- Home
- ACRS vs EVM Comparison
ACRS vs EVM Comparison
Compare ACRS & EVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- EVM
- Stock Information
- Founded
- ACRS 2012
- EVM 2002
- Country
- ACRS United States
- EVM United States
- Employees
- ACRS N/A
- EVM N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- EVM Finance/Investors Services
- Sector
- ACRS Health Care
- EVM Finance
- Exchange
- ACRS Nasdaq
- EVM Nasdaq
- Market Cap
- ACRS 198.2M
- EVM 235.5M
- IPO Year
- ACRS 2015
- EVM N/A
- Fundamental
- Price
- ACRS $1.89
- EVM $9.55
- Analyst Decision
- ACRS Strong Buy
- EVM
- Analyst Count
- ACRS 9
- EVM 0
- Target Price
- ACRS $9.25
- EVM N/A
- AVG Volume (30 Days)
- ACRS 1.1M
- EVM 55.8K
- Earning Date
- ACRS 11-05-2025
- EVM 01-01-0001
- Dividend Yield
- ACRS N/A
- EVM 4.01%
- EPS Growth
- ACRS N/A
- EVM N/A
- EPS
- ACRS N/A
- EVM 0.20
- Revenue
- ACRS $16,789,000.00
- EVM N/A
- Revenue This Year
- ACRS N/A
- EVM N/A
- Revenue Next Year
- ACRS $7.02
- EVM N/A
- P/E Ratio
- ACRS N/A
- EVM $47.61
- Revenue Growth
- ACRS N/A
- EVM N/A
- 52 Week Low
- ACRS $1.05
- EVM $7.67
- 52 Week High
- ACRS $5.17
- EVM $9.59
- Technical
- Relative Strength Index (RSI)
- ACRS 48.51
- EVM 67.29
- Support Level
- ACRS $1.81
- EVM $9.53
- Resistance Level
- ACRS $1.94
- EVM $9.74
- Average True Range (ATR)
- ACRS 0.09
- EVM 0.07
- MACD
- ACRS -0.01
- EVM -0.01
- Stochastic Oscillator
- ACRS 27.51
- EVM 37.59
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.